Lexicon Pharmaceuticals Inc (LXRX)
Lexicon Pharmaceuticals, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing medicines for human disease. Its portfolio includes sotagliflozin, an orally delivered small-molecule therapy being developed for hypertrophic cardiomyopathy, and ZYNQUISTA (sotagliflozin) for type 1 diabetes. The company also markets INPEFA (sotagliflozin), a once-daily oral tablet indicated to help reduce the risk of cardiovascular death, hospitalization for heart failure, and urgent heart failure visits in adults with heart failure or type 2 diabetes, chronic kidney disease, and other cardiovascular risk factors. Additional development programs include LX9851 for obesity and related cardiometabolic disorders and pilavapadin (LX9211) for neuropathic pain. Lexicon Pharmaceuticals has strategic collaboration and license agreements with Viatris Inc. and Bristol-Myers Squibb Company. Founded in 1995, it is headquartered in The Woodlands, Texas.
Jump between the core stock analysis sections, valuation data, fair value models, technical outlook, and FAQ.
| Ticker | Fair Value | Fair Value Upside/Downside | Fair Value Rating | Analyst Price Target | Analyst Target Upside/Downside | Analyst Target Rating | Overall Financial Health | Upcoming Dividend Ex-Date | Dividend Payment Date | Upcoming Dividend | Dividend Yield | Next Earnings Date | P/E Ratio | Price-to-Book Ratio | Price-to-Sales Ratio | Market Cap | Enterprise Value | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Payout Ratio | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
NASDAQ-LXRX
|
$1.75
|
-24.6% Downside
|
Overvalued
|
$3.77
|
62.2% Upside
|
Bargain
|
Great
|
—
|
—
|
—
|
0.0%
|
July 30, 2026
|
-39.4x
|
5.1x
|
14.8x
|
1.035 B
|
915.4 M
|
5.3%
|
59.1%
|
-2.3
|
—
|
148.7%
|
